To include your compound in the COVID-19 Resource Center, submit it here.

Amicus’ Batten disease gene therapy shows preserved speech, motor function

Interim data for Amicus’ most advanced Batten disease gene therapy suggest that the biotech’s recent addition of the modality to its pipeline could be paying off.

On Thursday, Amicus reported interim Phase I/II data showing its AAV-CLN6 gene therapy stabilized motor and speech functions in children with neuronal ceroid

Read the full 484 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers